April 26, 2011 -
PRLog -- Salt Lake City, UT – April 26, 2011 – Aciont Inc. announced today that the company will present findings on the ocular iontophoresis of macromolecules at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Fort Lauderdale, FL. Iontophoresis is a minimally invasive means to deliver drugs through tissue using a mild electrical current. “A number of research publications (in the transscleral iontophoresis area) are focusing on scleral tissue. This study reveals the importance of conjunctiva in ocular drug delivery, particularly when attempting to use in vitro results to predict the outcome of in vivo transscleral iontophoresis,”
said Dr. Kongnara Papangkorn, Aciont’s Director of Research.
The lead author of the presentation is Dr. Sarah A. Molokhia who works with the John A. Moran Eye Center at The University of Utah. The poster A497 is titled “Importance of the Conjunctiva in Transscleral Iontophoresis,”
and can be viewed on Tuesday May 3, 2011 from 1:45 – 3:30PM in Hall B/C at the Greater Fort Lauderdale Convention Center. Aciont personnel will be in attendance at the ARVO meeting to respond to questions regarding Aciont’s work.
------
Aciont Inc. is a specialty biopharmaceutical company endeavoring to become the world leader in commercializing localized, non-invasive (topical passive diffusion-based and iontophoretic)
, controlled and sustained release back of the eye therapeutics for sight threatening diseases such as severe uveitis, diabetic macular edema and age-related macular degeneration. Aciont’
s goal is to provide ophthalmologists substantially greater freedom in treating and/or preventing chronic eye diseases through optimal drug dosing and improved patient/physician compliance. Aciont is located in Salt Lake City, Utah. For more information, visit the company’s website at www.aciont.com.
Source: Aciont Inc.
Contact
John Higuchi, CEO
Aciont, Inc.
(801) 359-3461
admin@aciont.com
